AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
- Posted on September 8, 2026
- By CNBC
- 0 Views
- 1 min read
In brief
Generating AI summary…
AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.